Algernon Pharmaceuticals (TSE:AGN)
:AGN
Top Page
Algernon Pharmaceuticals
(AGN)
Select Model
Select Model
Rating:47Neutral
Price Target:
C$0.04
▼(-26.67% Downside)
Action:ReiteratedDate:03/27/26
The score is primarily held back by very weak fundamentals (no revenue, continued losses, and ongoing cash burn), despite improvement in loss and burn rates and a debt-free balance sheet. Technicals show short-term strength but are overextended and still below longer-term trend levels. Valuation is constrained by negative earnings and no dividend support.
Positive Factors
Debt-free balance sheet
Having no debt is a durable structural advantage for a clinical-stage biotech. It lowers fixed interest obligations, reduces bankruptcy and covenant risk, and gives management flexibility to allocate scarce cash to R&D or partnering. It also improves negotiating leverage when raising capital or structuring collaborations.
Negative Factors
Zero revenue
No revenue is a fundamental constraint: without product sales the company cannot internally finance operations, validate commercial demand, or demonstrate recurring cash generation. This structural state forces reliance on external funding and keeps long-term sustainability contingent on successful clinical outcomes or partnering.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
Having no debt is a durable structural advantage for a clinical-stage biotech. It lowers fixed interest obligations, reduces bankruptcy and covenant risk, and gives management flexibility to allocate scarce cash to R&D or partnering. It also improves negotiating leverage when raising capital or structuring collaborations.
Read all positive factors
Algernon Pharmaceuticals (AGN) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$2.56M
Dividend YieldN/A
Average Volume (3M)13.80K
Price to Earnings (P/E)―
Beta (1Y)<0.01
Revenue GrowthN/A
EPS Growth64.77%
CountryCA
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding46,499,270
10 Day Avg. Volume14,017
30 Day Avg. Volume13,803
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.77
Price to Sales (P/S)0.00
P/FCF Ratio-1.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Algernon Pharmaceuticals Business Overview & Revenue Model
Company Description
Algernon Pharmaceuticals Inc. operates as a clinical stage pharmaceutical development company. It focuses on the areas of nonalcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cou...
How the Company Makes Money
null...
Algernon Pharmaceuticals Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
48
Neutral
Cash Flow
22
Negative
| Breakdown | Nov 2025 | Nov 2024 | Nov 2023 | Aug 2022 | Aug 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -54.69K | -26.56K | -50.40K | -34.94K | 0.00 |
| EBITDA | -1.66M | -476.42K | -4.98M | -6.02M | -8.05M |
| Net Income | -1.72M | -502.98K | -6.78M | -6.05M | -7.73M |
Balance Sheet | |||||
| Total Assets | 4.88M | 3.94M | 4.19M | 8.14M | 10.14M |
| Cash, Cash Equivalents and Short-Term Investments | 176.50K | 596.20K | 125.08K | 1.41M | 2.41M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 2.18M | 1.78M | 2.72M | 2.52M | 1.02M |
| Stockholders Equity | 2.70M | 2.17M | 1.47M | 5.62M | 9.12M |
Cash Flow | |||||
| Free Cash Flow | -1.16M | -2.79M | -2.61M | -3.06M | -7.95M |
| Operating Cash Flow | -1.16M | -2.71M | -2.55M | -2.91M | -7.82M |
| Investing Cash Flow | 150.03K | 2.28M | -59.50K | -144.61K | -124.45K |
| Financing Cash Flow | 587.31K | 901.09K | 1.33M | 2.06M | 4.25M |
Algernon Pharmaceuticals Technical Analysis
Positive
0.06
Price Trends
0.04
Positive
0.06
Negative
0.06
Negative
Market Momentum
<0.01
Negative
59.77
Neutral
50.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:AGN, the sentiment is Positive. The current price of 0.06 is above the 20-day moving average (MA) of 0.05, above the 50-day MA of 0.04, and below the 200-day MA of 0.06, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 59.77 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:AGN.
Algernon Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
TSE:AGN
Algernon Pharmaceuticals
0.06
-0.03
-35.29%
TSE:APLI
Appili Therapeutics Inc Class A
0.02
-0.02
-50.00%
TSE:RKV
Rakovina Therapeutics Inc
0.10
-0.46
-82.73%
TSE:IBO
Universal Ibogaine Inc
0.01
-0.02
-66.67%
TSE:MBIO
Mindbio Therapeutics Corp.
1.10
-2.90
-72.50%
TSE:NURL
Neural Therapeutics Inc.
0.02
-0.02
-50.00%
Algernon Pharmaceuticals Corporate Events
Business Operations and StrategyStock Split
Algernon Health to Rebrand as Grey Matters and Enact 10-for-1 Share Consolidation
Positive
Apr 1, 2026
Algernon Health Inc. plans to change its corporate name to Grey Matters Health Inc., aligning its brand with an expanding focus on Alzheimer’s disease diagnostics and brain health. The rebranding supports the rollout of NovaScan Neuroimaging...
Business Operations and StrategyProduct-Related Announcements
Algernon Health Rebrands U.S. Brain PET Network as NovaScan Neuroimaging Clinics
Positive
Mar 27, 2026
Algernon Health has unveiled NovaScan Neuroimaging Clinics as the new brand and visual identity for its planned U.S. network of dedicated brain PET scanning centers, anchored by an inaugural facility in the HCA Florida University Medical Offices b...
Business Operations and StrategyPrivate Placements and Financing
Algernon to Launch First U.S. Brain-Dedicated PET Clinic in Florida as It Builds National Network
Positive
Mar 24, 2026
Algernon Health will open its first brain-dedicated PET scanning clinic at the HCA Florida University Medical Office Building in Davie, on the campus of HCA Florida University Hospital, under a five-year lease with an option to renew. The clinic, ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.